Ten-year trends in cardiovascular risk factors among patients hospitalised with acute myocardial infarction in Estonia: a retrospective nationwide observational study
Open Access
- 4 July 2026
- journal article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Abstract
Cardiovascular risk-factor profiles among patients hospitalised with acute myocardial infarction (AMI) can inform surveillance of a high-risk clinical cohort, but do not directly represent risk-factor prevalence in the general population. We analysed aggregate annual Estonian AMI registry data for hospitalised AMI patients during 2015-2024. AMI04 risk-factor trends were assessed using ordinary least squares regression, with sensitivity analyses for known status, age-sex standardisation to the pooled hospitalised AMI cohort, COVID-period exclusion, AMI case mix, and national hospitalised AMI burden. Documented smoking increased from 25.5% in 2015 to 28.1% in 2024 (β = 0.302% points/year; 95% CI 0.014 to 0.590; p = 0.042). The smoking trend remained significant in known-status analyses and after age-sex standardisation, although the crude observed trend became borderline after excluding 2020-2021. Documented dyslipidaemia increased descriptively, but full-period crude and age-sex-standardised trends were borderline, and unknown dyslipidaemia status decreased over time. Annual AMI attacks and national hospitalised AMI burden declined, with concurrent changes in sex and age composition. Among hospitalised AMI patients in Estonia, documented smoking increased during 2015-2024 and remained consistent in known-status and age-sex-standardised sensitivity analyses. Dyslipidaemia trends require cautious interpretation because unknown status changed over time. These aggregate registry findings describe a selected hospitalised AMI cohort and should not be interpreted as direct evidence of national prevention-policy success or failure.Keywords
This publication has 38 references indexed in Scilit:
- Prevalence of elevated lipoprotein(a) levels and associated atherosclerotic cardiovascular diseases in subjects with metabolic disorders: A real-world study in a lipid unitClínica e Investigación en Arteriosclerosis, 2026
- The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive CardiologyAmerican Journal of Preventive Cardiology, 2025
- Prevalence of hypertriglyceridemia and its association with extreme cardiovascular risk in patients with acute and chronic coronary syndrome enrolled in a cardiac rehabilitation programInternational Journal of Cardiology, 2025
- Trends in avoidable mortality from cardiovascular diseases in the European Union, 1995–2020: a retrospective secondary data analysisThe Lancet Regional Health - Europe, 2024
- Secondary prevention and extreme cardiovascular risk evaluation (SEVERE-0): Prevalence of extreme cardiovascular risk in cardiological rehabilitation patients and its impact on functional improvementNutrition, Metabolism and Cardiovascular Diseases, 2024
- Traditional risk factors and premature acute coronary syndromes in South Eastern Europe: a multinational cohort studyThe Lancet Regional Health - Europe, 2024
- Cardiovascular disease care and outcomes in West and South European countriesThe Lancet Regional Health - Europe, 2023
- 30 years of primary health care reforms in Estonia: The role of financial incentives to achieve a multidisciplinary primary health care systemHealth Policy, 2023
- Trends in 10-Year Outcomes Among Medicare Beneficiaries Who Survived an Acute Myocardial InfarctionJAMA Cardiology, 2022
- Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetesMetabolism, 2021